HCC CONNECT update from AASLD #3
HCC CONNECT update from AASLD #3
Asst. Prof. Sadahisa Ogasawara
HCC CONNECT has summarised the highlights of the recent congress of the American Association for the Study of Liver Diseases (AASLD) 2016 in Boston for you.Asst. Prof. Sadahisa Ogasawara
Gastroenterologist and Hepatologist
Chiba University
Japan
Dr. Sadahisa Ogasawara obtained his medical degree in 2004 and his PhD in 2012 from Chiba University (Japan). He is a hepatologist and works at Chiba University Hospital. He is currently an Assistant Professor of the cranial research center at Chiba University Hospital as well as on the staff of the Department of Gastroenterology, Chiba University, Graduate School of Medicine, where his research is focused on loco-regional treatments and systemic therapies of hepatocellular carcinoma.
Relevant Publications
Ogasawara S, Chiba T, Motoyama T, Kanogawa N, Saito T, Shinozaki Y, Suzuki E, Ooka Y, Tawada A, Kato H, Okabe S, Kanai F, Yoshikawa M, Yokosuka O. Prognostic significance of concurrent hypovascular and hypervascular nodules in patients with hepatocellular carcinoma. PLoS One 2016 Sep 20; 11(9): e0163119.
Ogasawara S, Chiba T, Ooka Y, Suzuki E, Inoue M, Wakamatsu T, Tawada A, Yokosuka O. Analysis of sorafenib outcome: focusing on the clinical course in patients with hepatocellular carcinoma. PLoS One 2016 Aug 18; 11(8): e0161303.
Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Azemoto R, Shinozaki M, Yoshikawa M, Yokosuka O. A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization. PLoS One 2015 Apr 28; 10(4): e0125244.
Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015 Jun; 33(3): 729-39.
Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 2014; 87(6): 330-41.
Conference Update |
5 min
|
2016
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.